Evidence map›Paper›PMID 39649700›Full record

ArticleFrontiers in molecular biosciences2024

Visualization of argininosuccinate synthetase by

Xia Gu, Wenhui Mo, Guiying Zhuang, Congcong Shi, Tao Wei, Jinze Zhang, Chiaowen Tu, Yao Cai, Biwen Liao, Hu Hao

Abstract read
In one paragraph

Article in Frontiers in molecular biosciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xia Gu *Department of Neonatology, The Sixth Affiliated Hospital, Sun-Yat-Sen University, Guangzhou, China.
Wenhui Mo *Department of Neonatology, Foshan Fosun Chancheng Hospital, Foshan, China.
Guiying Zhuang *Department of Neonatology, The Maternal and Child Health Care Hospital of Huadu, Guangzhou, China.
Congcong ShiBiomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Tao WeiGuangdong Shaohe Biotechnology Co., LTD., Guangzhou, China.
Jinze ZhangGuangdong Shaohe Biotechnology Co., LTD., Guangzhou, China.
Chiaowen TuDepartment of Neonatology, Foshan Fosun Chancheng Hospital, Foshan, China.
Yao CaiDepartment of Neonatology, The Sixth Affiliated Hospital, Sun-Yat-Sen University, Guangzhou, China.
Biwen LiaoDepartment of Neonatology, Foshan Fosun Chancheng Hospital, Foshan, China.
Hu HaoDepartment of Neonatology, The Sixth Affiliated Hospital, Sun-Yat-Sen University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Citrullinemia type I disorders (CTLN1) is a genetic metabolic disease caused by argininosuccinate synthetase (ASS1) gene mutation. To date, the human genome mutation database has documented over 100 variants of the ASS1 gene. This study reported a novel deletion-insertion variant of ASS1 gene and employed various prediction tools to determine its pathogenicity. Methods: We reported a case of early-onset CTLN1. Whole exome sequencing was conducted to identify genetic mutations. We employed various structure prediction tools to generate accurate 3D models and utilized computational biology tools to elucidate the disparities between the wild-type and mutant proteins. Results: The patient was characterized by severe clinical manifestations, including poor responsiveness, lethargy, convulsions, and cardiac arrest. Notably, the patient exhibited significantly elevated blood ammonia levels (655 μmol/L; normal reference: 10-30 μmol/L) and increased citrulline concentrations (936 μmol/L; normal reference: 5-25 μmol/L). Whole exome sequencing revealed a in-frame deletion-insertion mutation Conclusion: Through conducting an in silico analysis on this unique in-frame deletion-insertion variant of ASS1, our aim was to enhance understanding regarding its structure-function relationship as well as unraveling the molecular mechanism underlying CTLN1.

Indexed as

argininosuccinate synthetasecitrullinemia type Ideletion-insertion variantsin silico analysismolecular dynamics simulation

Identifiers

PMID39649700
PMCPMC11621003

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.